L 663536
From Wikipedia, the free encyclopedia
(Redirected from MK-886)
 |
|
 |
|
| Names | |
|---|---|
| IUPAC name
3-[3-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-yl-indol-2-yl]-2,2 -dimethyl-propanoic acid
|
|
| Other names
MK 886
|
|
| Identifiers | |
118414-82-7  |
|
| MeSH | L+663536 |
| PubChem | 105049 |
| Properties | |
| C27H34ClNO2S | |
| Molar mass | 472.083 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
 verify (what is  ?) |
|
| Infobox references | |
L 663536 is a leukotriene antagonist. It may perform this by blocking the 5-lipoxygenase activating protein (FLAP), thus inhibiting 5-lipoxygenase (5-LOX),[1] and may help in treating atherosclerosis.[2]
References[edit]
- ^ Jun, Joon-Il; Lau, Lester F. (July 2010). "The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing". Nature Cell Biology. 12 (7): 676–685. doi:10.1038/ncb2070. ISSN 1465-7392. PMC 2919364
. PMID 20526329. Retrieved 2011-08-28. - ^ Jawien, J.; Gajda, M.; Rudling, M.; Mateuszuk, L.; Olszanecki, R.; Guzik, T. J.; Cichocki, T.; Chlopicki, S.; Korbut, R. (March 2006). "Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice". European Journal of Clinical Investigation. 36 (3): 141–146. doi:10.1111/j.1365-2362.2006.01606.x. PMID 16506957.
.svg){kind=small} |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
